Literature DB >> 15734072

Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice.

Ricky L Ulrich1, Kei Amemiya, David M Waag, Chad J Roy, David DeShazer.   

Abstract

Burkholderia mallei is an obligate mammalian pathogen that causes the zoonotic disease glanders. Two live attenuated B. mallei strains, a capsule mutant and a branched-chain amino acid auxotroph, were evaluated for use as vaccines against aerosol-initiated glanders in mice. Animals were aerogenically vaccinated and serum samples were obtained before aerosol challenge with a high-dose (>300 times the LD50) of B. mallei ATCC 23344. Mice vaccinated with the capsule mutant developed a Th2-like Ig subclass antibody response and none survived beyond 5 days. In comparison, the auxotrophic mutant elicited a Th1-like Ig subclass antibody response and 25% of the animals survived for 1 month postchallenge. After a low-dose (5 times the LD50) aerosol challenge, the survival rates of auxotroph-vaccinated and unvaccinated animals were 50 and 0%, respectively. Thus, live attenuated strains that promote a Th1-like Ig response may serve as promising vaccine candidates against aerosol infection with B. mallei.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734072     DOI: 10.1016/j.vaccine.2004.10.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  The animal pathogen-like type III secretion system is required for the intracellular survival of Burkholderia mallei within J774.2 macrophages.

Authors:  Wilson J Ribot; Ricky L Ulrich
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Genetic tools for allelic replacement in Burkholderia species.

Authors:  Ashley R Barrett; Yun Kang; Ken S Inamasu; Mike S Son; Joseph M Vukovich; Tung T Hoang
Journal:  Appl Environ Microbiol       Date:  2008-05-23       Impact factor: 4.792

3.  Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages.

Authors:  Mary N Burtnick; David DeShazer; Vinod Nair; Frank C Gherardini; Paul J Brett
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

4.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

5.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

6.  Pathological findings and diagnostic implications of a rhesus macaque (Macacca mulatta) model of aerosol exposure to Burkholderia mallei (glanders).

Authors:  Samuel L Yingst; Paul Facemire; Lara Chuvala; David Norwood; Mark Wolcott; Louis Huzella
Journal:  J Med Microbiol       Date:  2015-04-07       Impact factor: 2.472

7.  The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice.

Authors:  Michael H Norris; Katie L Propst; Yun Kang; Steven W Dow; Herbert P Schweizer; Tung T Hoang
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

Review 8.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

9.  Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.

Authors:  Sylvia R Treviño; Amy R Permenter; Marilyn J England; Narayanan Parthasarathy; Paul H Gibbs; David M Waag; Tran C Chanh
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.